麦肯锡的高见

Happen to see a McKinsey report dated 2002 at work. It's about the biotech industry. It claims that due to rapid development in this field, high level talents, i.e., Ph.Ds in cellular biology, biochemistry, molecular biology etc. will be in extremely short demand until at least 2010.

This is beyond stupidity. We are not even talking about giving a wrong forecast. Bio Ph.Ds have been languishing in the job market since well well before 2002. These McKinsey boys did not even get their facts straight before making some grandiose statement. I have been always curious what these management consultants do and I do hope this does not truly reflect their work.

An eventful time in the generic industry

1. After all those acquisitions, Actavis decided to go private.
2. Mylan spent more than its own worth buying Merck KGaA's generic unit.
3. After all the wizards from the Street predicted a generic win, Teva lost Aciphex case.

Mylan bought Merck KGaA generic unit for $6.6B

The landscape is changing again. In a sense, Mylan might have to get this to continue the growth of the company. The fact they outbid Teva and some equity firms attests to that.

两条FDA的新闻

FDA今天的email newsletter里有两条与中国有关的新闻。第一是关于在饲料中添加melamine的，第二是关于检查glycerin的质量。

Talk about Globalization!

Aids drug in Thailand and Brazil

继前几天泰国宣布对Abbott的一个药实行强制授权后，巴西今天对BMS作出了类似的威胁。
这里面能有什么商机吗？